• Go to navigation
  • Go to content
AstraZeneca

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca United States

Main navigation

  • Home
  • Our medicines
  • Diseases and conditions
  • Community support
  • Help affording your medicines
  • Research & development
  • Healthcare professionals
  • Careers
  • About AstraZeneca US
    • Investors
    • Our company
    • AZ on the issues
    • Responsible business
    • Newsroom
    • US web sites
    • Contact us

You are here

  • Home
  • About AstraZeneca US
  • Contact us
  • Media resources

Helpful resources for media professionals.

This information is intended for media professionals only, and AstraZeneca media contacts may ONLY respond to professional journalists.

If you are not a journalist working for a news organization, or if your inquiry is for advertising or vendor offers of service, please visit the contact us page.

Please note, it is against AstraZeneca policy to provide a list of our vendors to members of the media.

AstraZeneca media contacts for qualified journalists 

Corporate Media Relations:

  • Tony Jewell: 1-302-885-4594
  • Laura Woodin: 1-302-885-1087 

Brand Media Relations:

  • Steve Lampert (All Brands): 1-302-886-7862
  • Julia Walker (CRESTOR, CERTRIAD, BRILINTA & ONGLYZA): 1-302-885-5172
  • Kirsten Evraire (SEROQUEL, SYMBICORT, & VIMOVO): 1-302-885-0435  
  • Blair Hains (NEXIUM, MERREM, TOPROL-XL, ATACAND & ZOMIG): 1-302-885-1813
  • Emily Denney (Phase II & III Development Compounds: ZACTIMA, RECENTIN, Zibotentan, Dapagliflozin, NKTR-118, & Olaparib): 1-302-885-3451 

Additional resources for media professionals

  •  AstraZeneca US backgrounder (fact sheet)
  •  AstraZeneca US boilerplate  
  • AstraZeneca US executive leadership team bios

Page tools

  • Print
  • Bookmark this page
  • Subscribe to RSS news feed

Help affording your medicines

Help affording your medicines

  • Find out if you may be eligible for one of the AZ&Me™ Prescription Savings programs

Legal notices

  • Legal Information
  • Privacy Statement
  • © AstraZeneca 2009